Clinical trials in Le Chesnay-Rocquencourt – page 45

3 344 clinical trials in Le Chesnay-Rocquencourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Le Chesnay-Rocquencourt at a glance

3 344

clinical trials

Research sites1

Quick filters

3 344 trials in Le Chesnay-Rocquencourt

Open in trial search

Hepatocellular carcinoma

Recruiting

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Daraxonrasib
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Endocarditis staphylococcal

Recruiting

Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

Registered drugNo placebo

Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cefazolin Sodium
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Autoimmune haemolytic anaemia

Recruiting

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

France

Participants:18–64 years · 65+ years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lutetium (177LU) vipivotide tetraxetan
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

France

Participants:18–64 years · 65+ years
Substances:Ibuzatrelvir
Sponsor:Pfizer Inc.

Contact Research Centre

K-ras gene mutation+1

Recruiting

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Dementia Alzheimer's type

Recruiting

Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer's Disease

Investigational

Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer's Disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:LY3372993
Sponsor:Washington University School Of Medicine

Contact Research Centre

Fallopian tube cancer+1

Recruiting

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo

France

Participants:18–64 years
Substances:Prednisolone Acetate
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:BeOne Medicines AG

Contact Research Centre

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Le Chesnay-Rocquencourt

What the registry says about research in the country

01 Cardiology & Respiratory Medicine

Clinical trials focusing on acute myocardial infarction pain management and innovative treatments for severe asthma. Research includes evaluation of novel pain-relief methods and assessment of treatment discontinuation strategies.

Pain management in heart attacks
Asthma treatment optimization
Heart failure management

Studies also examine beta-blocker discontinuation in patients with recovered heart function.

02 Oncology & Hematology

Extensive research in blood cancers, including multiple myeloma, acute myeloid leukemia, and various lymphomas. Studies evaluate novel drug combinations and treatment strategies.

Blood cancer therapies
Leukemia treatments
Breast cancer management

Investigations include targeted therapies and personalized treatment approaches for various cancer types.

03 Pediatric & Infectious Diseases

Research focusing on respiratory syncytial virus (RSV) prevention in infants and children. Studies evaluate new protective treatments and their safety profiles.

RSV prevention
Infant protection studies
Immunotherapy research

Trials include assessment of novel medications for preventing severe respiratory infections in vulnerable populations.

Back to France All countries